All In Biotech

Drug Trial Radar · NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Mar 23, 2033

Study completion Dec 29, 2034

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy

Conditions

  • Breast Neoplasms
  • Triple Negative Breast Neoplasms
  • HR Low-Positive/HER2-Negative Breast Neoplasms

Interventions

  • Sacituzumab tirumotecanBiological

    IV infusion

  • PembrolizumabBiological

    IV infusion

  • Rescue MedicationDrug

    Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).

  • CarboplatinDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • DoxorubicinDrug

    IV infusion

  • EpirubicinDrug

    IV infusion

  • CyclophosphamideDrug

    IV infusion

  • CapecitabineDrug

    Oral tablet

  • OlaparibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive SurgeryTime frame: Up to approximately 30 weeks
  2. Event-Free Survival (EFS)Time frame: Up to approximately 92 months

Locations

338 sites in 41 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0066)

    Gilbert, Arizona · Recruiting

  • Mayo Clinic Cancer Center ( Site 0034)

    Phoenix, Arizona · Recruiting

  • University of Arizona Cancer Center ( Site 0035)

    Tucson, Arizona · Recruiting

  • Roy and Patricia Disney Family Cancer Center ( Site 0055)

    Burbank, California · Recruiting

  • Community Cancer Institute ( Site 0100)

    Clovis, California · Recruiting

  • Providence Medical Foundation ( Site 0080)

    Fullerton, California · Recruiting

  • MemorialCare Health System - Long Beach Medical Center ( Site 9556)

    Long Beach, California · Recruiting

  • El Camino Hospital Cancer Center ( Site 0096)

    Mountain View, California · Recruiting

  • Hoag Memorial Hospital Presbyterian ( Site 0010)

    Newport Beach, California · Recruiting

  • Helios Clinical Research ( Site 0061)

    Whittier, California · Recruiting

  • Intermountain Health Cancer Center Saint Joseph ( Site 0062)

    Denver, Colorado · Recruiting

  • Rocky Mountain Cancer Centers (RMCC) ( Site 8006)

    Denver, Colorado · Recruiting

  • Intermountain Health St. Mary's Regional Hospital ( Site 0054)

    Grand Junction, Colorado · Recruiting

  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044)

    Altamonte Springs, Florida · Recruiting

  • Florida Cancer Specialists - South ( Site 7004)

    Fort Myers, Florida · Recruiting

  • Bioresearch Partner ( Site 0072)

    Hialeah, Florida · Recruiting

  • Mayo Clinic Hospital ( Site 0013)

    Jacksonville, Florida · Recruiting

  • Florida Cancer Specialists - North ( Site 7002)

    St. Petersburg, Florida · Recruiting

  • City of Hope Cancer Center - Atlanta ( Site 0102)

    Newnan, Georgia · Recruiting

  • Southern Illinois Hospital Services ( Site 9554)

    Carterville, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology ( Site 0084)

    Fort Wayne, Indiana · Recruiting

  • Franciscan Health ( Site 0077)

    Indianapolis, Indiana · Recruiting

  • Ochsner Clinic Foundation ( Site 0021)

    New Orleans, Louisiana · Recruiting

  • Louisiana State University Health Sciences Shreveport ( Site 0053)

    Shreveport, Louisiana · Recruiting

  • New England Cancer Specialists ( Site 0051)

    Westbrook, Maine · Recruiting

  • Mercy Medical Center - Baltimore ( Site 0015)

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital Cancer Center ( Site 0091)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute ( Site 0090)

    Boston, Massachusetts · Recruiting

  • Saint Luke's Cancer Institute ( Site 0059)

    Kansas City, Missouri · Recruiting

  • Washington University Siteman Cancer Center ( Site 0031)

    St Louis, Missouri · Recruiting

  • Cancer Partners of Nebraska ( Site 0068)

    Lincoln, Nebraska · Recruiting

  • Optum Care Cancer Center ( Site 0050)

    Las Vegas, Nevada · Recruiting

  • Renown Regional Medical Center ( Site 0041)

    Reno, Nevada · Recruiting

  • Hackensack Univ Medical Center (HUMC) ( Site 0007)

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0076)

    New Brunswick, New Jersey · Recruiting

  • Altru Health System ( Site 0057)

    Grand Forks, North Dakota · Recruiting

  • Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)

    Cincinnati, Ohio · Recruiting

  • Northwest Cancer Specialists (Compass Oncology) ( Site 8010)

    Tigard, Oregon · Recruiting

  • Medical University of South Carolina-Hollings Cancer Center ( Site 0016)

    Charleston, South Carolina · Recruiting

  • St Francis Cancer Center ( Site 0093)

    Greenville, South Carolina · Recruiting

Showing 40 of 338 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.